Abstract
Yuan-Ying Su, Fang-Yuan Ji, Ze-Jun Zheng, Jiang-Yun Peng, Jian-Jun Xie
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
No local reference links have been materialized yet.
No local citing links have been materialized yet.
10.1186/s13046-023-02763-5
10.1186/s13046-023-02763-5
10.1016/j.cell.2013.03.035
10.1016/j.cell.2013.03.035
10.1016/j.pharmthera.2019.02.014
10.1016/j.pharmthera.2019.02.014
10.1038/s41467-018-03279-9
10.1038/s41467-018-03279-9
10.1038/nature25461
10.1038/nature25461
10.1016/j.cell.2023.12.005
10.1016/j.cell.2023.12.005
10.1016/j.cell.2023.11.030
10.1016/j.cell.2023.11.030
10.1038/35057062
10.1038/35057062
Upregulation of superenhancer-driven LncRNA FASRL by USF1 promotes de novo fatty acid biosynthesis to exacerbate hepatocellular carcinoma
10.1002/advs.202204711 · 2022
Super-enhancer-associated long noncoding RNA RP11-569A11.1 inhibited cell progression and metastasis by regulating IFIT2 in colorectal cancer
10.1002/jcla.23780 · 2021
Histone H3K4me1 strongly activates the DNase I hypersensitive sites in super-enhancers than those in typical enhancers
Confidence 92%
datacite
Confidence 0%
10.1042/bsr20210691 · 2021
10.3390/cancers14122866
10.3390/cancers14122866
Non-coding RNA in cancer
10.1042/ebc20200032 · 2021
10.1016/j.molcel.2013.01.038
10.1016/j.molcel.2013.01.038
10.1146/annurev-genom-122220-093818
10.1146/annurev-genom-122220-093818
10.1126/science.1172046
10.1126/science.1172046
10.1126/science.aar3958
10.1126/science.aar3958
10.1158/0008-5472.can-22-2433
10.1158/0008-5472.can-22-2433
Twist1-YY1-p300 complex promotes the malignant progression of HCC thro ugh activation of miR-9 by forming phase-separated condensates at supe r-enhancers and relieved by metformin
10.1016/j.phrs.2023.106661 · 2023
CYTOR facilitates formation of FOSL1 phase separation and super enhanc ers to drive metastasis of tumor budding cells in head and neck squamo us cell carcinoma
10.1002/advs.202305002 · 2023
10.1016/j.omtn.2023.03.014
10.1016/j.omtn.2023.03.014
10.1016/j.csbj.2021.05.006
10.1016/j.csbj.2021.05.006
10.1101/gr.197590.115
10.1101/gr.197590.115
10.1038/nature16546
10.1038/nature16546
10.1038/s41388-020-01459-w
10.1038/s41388-020-01459-w
10.1016/j.ccell.2018.11.001
10.1016/j.ccell.2018.11.001
10.1053/j.gastro.2020.06.050
10.1053/j.gastro.2020.06.050
Super-enhancer associated core regulatory circuits mediate susceptibil ity to retinoic acid in neuroblastoma cells
10.3389/fcell.2022.943924 · 2022
Parental imprinting of the mouse H19 gene
10.1038/351153a0 · 1991
10.1016/0092-8674(92)90520-m
10.1016/0092-8674(92)90520-m
10.1186/1476-4598-10-38
10.1186/1476-4598-10-38
10.1016/j.cell.2024.10.024
10.1016/j.cell.2024.10.024
10.1093/nar/gkaa1046
10.1093/nar/gkaa1046
LNCipedia 5: towards a reference set of human long non-coding RNAs
10.1093/nar/gky1031 · 2019
10.1038/onc.2017.184
10.1038/onc.2017.184
10.1242/jcs.009357
10.1242/jcs.009357
10.7554/elife.29224
10.7554/elife.29224
Gene regulation by long non-coding RNAs and its biological functions
10.1038/s41580-020-00315-9 · 2020
10.1101/gr.132159.111
10.1101/gr.132159.111
10.1371/journal.pgen.1003078
10.1371/journal.pgen.1003078
10.1056/nejmoa2210027
10.1056/nejmoa2210027 · doi-reference
The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits sele ctive activity in high-risk neuroblastoma
10.1038/s41467-021-26640-x · doi-reference
Risdiplam: first approval
10.1007/s40265-020-01410-z · doi-reference
Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma
10.1186/s12943-020-01236-z · doi-reference
10.1136/gutjnl-2016-311818
10.1136/gutjnl-2016-311818 · doi-reference
10.1038/nrclinonc.2016.26
10.1038/nrclinonc.2016.26 · doi-reference
10.3390/ijms21186479
10.3390/ijms21186479 · doi-reference
Correction: the CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
10.1038/s41416-024-02606-w · doi-reference
10.1158/0008-5472.can-19-0119
10.1158/0008-5472.can-19-0119 · doi-reference
10.1016/j.cell.2015.08.063
10.1016/j.cell.2015.08.063 · doi-reference
10.1016/j.cell.2014.10.024
10.1016/j.cell.2014.10.024 · doi-reference
10.1016/j.molcel.2015.06.032
10.1016/j.molcel.2015.06.032 · doi-reference
10.1016/j.ejmech.2023.116052
10.1016/j.ejmech.2023.116052 · doi-reference
10.1158/2767-9764.crc-23-0639
10.1158/2767-9764.crc-23-0639 · doi-reference
10.1038/leu.2013.338
10.1038/leu.2013.338 · doi-reference
10.1038/cr.2014.71
10.1038/cr.2014.71 · doi-reference
10.1038/nature10334
10.1038/nature10334 · doi-reference
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple mye loma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
10.1016/s2352-3026(16)00021-1 · doi-reference
3rd. bromodomains: a new target class for drug development
10.1038/s41573-019-0030-7 · doi-reference
10.1016/j.ccr.2013.11.003
10.1016/j.ccr.2013.11.003 · doi-reference
10.1016/j.cell.2013.03.036
10.1016/j.cell.2013.03.036 · doi-reference
Super enhancer-regulated LncRNA LINC01089 induces alternative splicing of DIAPH3 to drive hepatocellular carcinoma metastasis
10.1158/0008-5472.can-23-0544 · doi-reference
Anchoring super-enhancer-driven oncogenic lncRNAs for anti-tumor therapy in hepatocellular carcinoma
10.1016/j.ymthe.2022.11.013 · doi-reference
10.1016/j.isci.2019.06.025
10.1016/j.isci.2019.06.025 · doi-reference
LncRNA DSCAM-AS1 acts as a sponge of miR-137 to enhance tamoxifen resistance in breast cancer
10.1002/jcp.27105 · doi-reference
10.1016/j.molcel.2024.09.018
10.1016/j.molcel.2024.09.018 · doi-reference
Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer
10.1146/annurev.pa.35.040195.001211 · doi-reference
10.1016/j.bbcan.2021.188668
10.1016/j.bbcan.2021.188668 · doi-reference
METTL3-modified lncRNA DSCAM-AS1 promotes breast cancer progression through inhibiting ferroptosis
10.1007/s10863-024-10024-z · doi-reference
Genome-wide analysis of the FOXA1 transcriptional regulatory network identifies super enhancer associated LncRNAs in tamoxifen resistance
10.3389/fgene.2022.992444 · doi-reference
10.1038/cr.2014.35
10.1038/cr.2014.35 · doi-reference
Immune infiltration and clinical outcome of super-enhancer-associated lncRNAs in stomach adenocarcinoma
10.3389/fonc.2022.780493 · doi-reference
10.3390/cancers14163980
10.3390/cancers14163980 · doi-reference
10.1016/j.bbrc.2020.03.043
10.1016/j.bbrc.2020.03.043 · doi-reference
Bromodomain proteins epigenetically regulate the mitotically associate d lncRNA MANCR in triple negative breast cancer cells
10.1615/critreveukaryotgeneexpr.2023050109 · doi-reference
A novel oncogenic seRNA promotes nasopharyngeal carcinoma metastasis
10.1038/s41419-022-04846-1 · doi-reference
HSF1 stimulates glutamine transport by super-enhancer-driven lncRNA LINC00857 in colorectal cancer
10.3390/cancers14163855 · doi-reference
Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression
10.1038/s41467-018-06081-9 · doi-reference
10.1053/j.gastro.2018.02.018
10.1053/j.gastro.2018.02.018 · doi-reference
Super-enhancer-driven lncRNA LIMD1-AS1 activated by CDK7 promotes glioma progression
10.1038/s41419-023-05892-z · doi-reference